Original language | English |
---|---|
Pages (from-to) | e17-e20 |
Journal | CLINICAL BREAST CANCER |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2014 |
Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
Florian Huemer (First author), Simon Peter Gampenrieder (Co-author), Alexander Schlattau (Co-author), Richard Greil (Last author)
Research output: Contribution to journal › Case report › peer-review